https://doi.org/10.4081/tmr.6397

Vinflunine and bladder cancer: present and future indications

Vol. 5 No. 1 (2021)
Submitted: 18 November 2016
Accepted: 4 January 2017
Published: 20 February 2017
Bladder, Chemotherapy, Urothelial carcinoma, Vinca alkaloid, Vinflunine
Abstract Views: 1105
PDF: 515
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Giuseppina Della Vittoria Scarpati
Department of Radiation Therapy, University of Naples Federico II, Naples, Italy.
Francesco Perri
Medical Oncology Unit, SS. Annunziata Hospital, Taranto, Italy.
Matteo Ferro
Urology Division, European Institute of Oncology, Milan, Italy.
Carla Cavaliere
Medical Oncology Unit, SS. Annunziata Hospital, Taranto, Italy.
Gaetano Facchini
Division of Medical Oncology, Department of Uro-Gynaecological Oncology, National Tumor Institute of Naples “G. Pascale”, Naples, Italy.
Michele Caraglia
Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy.
Silvia Zappavigna
silvia.zappa@libero.it
Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy.
Raffaele Addeo
Oncology Unit, San Giovanni di Dio Hospital, Frattamaggiore (NA), Italy.
Urothelial cancer (UC) frequently affects male sex over the sixth decade of life, and in about 30% of the cases, it is diagnosed as muscle-invasive disease. For patients with metastatic disease, the prognosis is grim and the typical treatment is polychemotherapy involving cisplatin. Secondline chemotherapy is often employed, but a standard scheme does not exist. Vinflunine (VFL) is a new generation vinca alkaloid able to reversibly link the subunits of tubulin, causing the arrest of mitotic spindle polymerization. In critical trials, VFL has shown good activity and manageable toxicity; in a phase III randomized trial, it significantly improved survival compared with the best supportive care (BSC). VFL has received European Medicines Agency (EMA) approval for use as second-line treatment in UC patients who progressed after a first-line cisplatin-containing chemotherapy. Due to its low toxicity and promising efficacy, VFL is under clinical experimentations aimed to assess its role in other disease settings.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Silvia Zappavigna, Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples

Assistant Professor, Department of Biochemistry, Biophysics and General Pathology

Second University of Naples

How to Cite

Della Vittoria Scarpati, G., Perri, F., Ferro, M., Cavaliere, C., Facchini, G., Caraglia, M., Zappavigna, S., & Addeo, R. (2017). Vinflunine and bladder cancer: present and future indications. Translational Medicine Reports, 5(1). https://doi.org/10.4081/tmr.6397
Copyright (c) 2017 Giuseppina Della Vittoria Scarpati, Francesco Perri, Matteo Ferro, Carla Cavaliere, Gaetano Facchini, Michele Caraglia, Silvia Zappavigna, Raffaele Addeo Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.